

# Effect of sleeve gastrectomy on patients with or without preoperative gastroesophageal reflux disease

<b>Submission date</b> 24/03/2015	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 15/04/2015	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 24/07/2020	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Gastroesophageal reflux disease (GERD) is a common condition where stomach acids leak out into the oesophagus (gullet). Symptoms include heartburn, acid reflux (acid coming back up into the mouth), and difficulty and pain when swallowing. People who are overweight or obese are at high risk of developing GERD. In some cases, 24-hour pH monitoring is recommended to help diagnose the condition. This measures pH levels around the oesophagus to test for excess acid. Laparoscopic sleeve gastrectomy (LSG), where the stomach is made smaller to restrict the amount of food that can be eaten, has been found to work well in treating morbid (life-endangering) obesity based on both short and mid-term studies. However, there are concerns that LSG may lead to GERD or worsen existing GERD. There has not yet been any rigorous large studies investigating this using 24-hour pH monitoring. The aim of this study is to observe pH levels in the oesophagus in people having LSG using 24-hour pH monitoring.

### Who can participate?

Adults who are obese and scheduled to have LSG surgery.

### What does the study involve?

Each participant undergoes 24-hour pH monitoring just before they have their LSG surgery. Six months following surgery, they then have a usual full clinical and biological examination and are invited to undergo 24-h pH monitoring again to test for GORD.

### What are the possible benefits and risks of participating?

Participants enjoy the benefit of a gold standard test to test for GERD in clinical practice. No major adverse outcomes have been reported with such a test.

### Where is the study run from?

The University Nutrition Department at Ambroise Paré University Hospital, West Paris (France)

### When is the study starting and how long is it expected to run for?

January 2012 to April 2015

Who is funding the study?  
Investigator initiated and funded

Who is the main contact?  
Dr Sébastien Czernichow

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Sébastien Czernichow

**Contact details**  
Departement of Nutrition  
CHU Ambrosie Paré  
Boulogne-Billancourt  
France  
92100

**Type(s)**  
Public

**Contact name**  
Dr Jérémie Thereaux

**ORCID ID**  
<http://orcid.org/0000-0002-7361-9811>

**Contact details**  
Departement of Nutrition  
CHU Ambrosie Paré  
Boulogne-Billancourt  
France  
92100

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers  
N/A

## Study information

**Scientific Title**

Effect of sleeve gastrectomy on patients with or without preoperative gastroesophageal reflux disease: a pH-metry based study

**Study objectives**

Gastroesophageal reflux disease is a frequent obesity-related co-morbidity which is objectively assessed by 24-h pH monitoring. Sleeve gastrectomy (LSG) has been found as an effective treatment for morbid obesity based on short and mid term studies. However, some concerns have been raised on LSG with the unpredictable risk of de novo or worsening GERD. Rigorous large studies using 24-h pH monitoring are lacking. The aim of our study was to assess post operative influence of sleeve gastrectomy (LSG) on GERD in obese morbid patients with or without preoperative GERD.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Observational study

**Study design**

Patients scheduled for sleeve gastrectomy were offered to undergo 24-h pH monitoring in the preoperative time and 6 months after surgery.

**Primary study design**

Observational

**Secondary study design****Study setting(s)**

Hospital

**Study type(s)**

Quality of life

**Participant information sheet****Health condition(s) or problem(s) studied**

Grade 3 obesity

**Interventions**

Laparoscopic sleeve gastrectomy:

The aim of our study is to determine whether sleeve gastrectomy leads to de novo gastroesophageal reflux disease or exacerbates preoperative GERD in morbidly obese patients. Ambulatory esophageal pH monitoring is the gold standard for the diagnosis of gastroesophageal reflux disease. The nasoesophageal catheter was placed 5 cm above upper border of the lower esophageal sphincter. Esophageal pH monitoring was performed for 24 hours. There were recorded total, supine and upright time with esophageal pH<4. Patients were offered to undergo the 24-h pH monitoring preoperatively and 6 months after the bariatric procedure.

**Intervention Type**

Procedure/Surgery

**Primary outcome measure**

Percentage with esophageal pH<4 for total time ≥4.2%.

**Secondary outcome measures**

Percentage with esophageal pH<4 for upright and supine time ≥4.2%.

**Overall study start date**

01/01/2012

**Completion date**

01/04/2015

## **Eligibility**

**Key inclusion criteria**

1. Adults patients
2. Body Mass Index >35 kg/m<sup>2</sup>
3. Eligible for bariatric surgery
4. Preoperative medical management > 6 months
5. According to NIH/HAS criteria for bariatric surgery

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

90

**Total final enrolment**

89

**Key exclusion criteria**

1. Refusal
2. Huge Hiatal Hernia
3. History of hiatal surgery
4. Pregnancy

**Date of first enrolment**

01/07/2012

**Date of final enrolment**

15/09/2014

# Locations

## Countries of recruitment

France

## Study participating centre

**CHU Ambroise Paré**

Boulogne-Billancourt

France

92100

# Sponsor information

## Organisation

CHU Ambroise Paré

## Sponsor details

Avenue Charles de Gaulle

Boulogne-billancourt

France

92100

## Sponsor type

Hospital/treatment centre

## ROR

<https://ror.org/03j6rvb05>

# Funder(s)

## Funder type

Not defined

## Funder Name

Investigator initiated and funded

# Results and Publications

## Publication and dissemination plan

The results of the study will be published in a peer-reviewed scientific journals and presented at conferences (years 2015-2016)

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not expected to be made available

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/03/2016	24/07/2020	Yes	No